STOCK TITAN

Bruker Corporation (BRKR) Stock News, Apr-May 2022

BRKR NASDAQ

Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.

Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.

News
Rhea-AI Summary

Bruker Corporation (NASDAQ: BRKR) announced the approval of a quarterly cash dividend of $0.05 per share. This dividend will be paid on June 17, 2022, to stockholders of record as of June 1, 2022.

Bruker is dedicated to advancing scientific discovery through high-performance instruments and analytical solutions that enhance human life quality. The company operates in various domains including life sciences, applied markets, and industrial applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.10%
Tags
dividends
-
Rhea-AI Summary

Bruker Corporation (BRKR) has entered a strategic partnership with TOFWERK AG, including a minority investment by Bruker in TOFWERK. This collaboration focuses on enhancing high-speed and ultra-sensitive analytical solutions, particularly in mass spectrometry for small molecules and volatile compounds. The partnership aims to leverage Bruker’s commercial scale to boost TOFWERK’s market presence. Innovations include advanced instrument capabilities and applications for ambient air analysis, breath diagnostics, and semiconductor monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.50%
Tags
partnership
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.72%
Tags
none
Rhea-AI Summary

Bruker Corporation reported Q1 2022 revenues of $595.0 million, a 7.3% year-over-year increase. Organic revenue growth was notable at 10.5%. The company saw GAAP diluted EPS rise to $0.41, up from $0.37 in Q1 2021. With strong demand for its life science tools, Bruker raised its FY 2022 organic revenue outlook to 7% to 9% and expects non-GAAP EPS between $2.29 to $2.33, reflecting a 9% to 11% increase year-over-year. The firm also made key acquisitions to bolster growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
-
Rhea-AI Summary

Bruker recently showcased its innovative Ascend Evo 1.0 GHz NMR magnet at the Experimental Nuclear Magnetic Resonance Conference, designed to operate at 4.2 Kelvin for structural biology in standard labs. This new technology boasts a significant reduction in liquid helium consumption by threefold, enhancing accessibility for researchers. Additionally, Bruker introduced the Heliosmart Recovery system which enables the collection of helium gas boil-off, achieving recovery rates of 80%-85%. The company continues to offer services like LabScape Remote Monitoring for effective management of NMR magnets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
-
Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) recently introduced advancements in its MALDI Biotyper® platform and launched new multiplex PCR assays at the 32nd European Congress of Clinical Microbiology & Infectious Diseases. Key offerings include the FluoroType® Mycobacteria PCR assay, which differentiates 32 mycobacteria species, and the FluoroType® STI PCR assay, which detects seven major STI pathogens. These innovations enhance Bruker's portfolio in infectious disease diagnostics, leveraging its LiquidArray® technology for improved accuracy and speed in clinical settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
Rhea-AI Summary

Bruker Corporation (NASDAQ: BRKR) will report its first quarter 2022 financial results on May 4, 2022, before market opening. A conference call and webcast will take place at 8:30 a.m. Eastern Time to discuss these results and current business trends. Investors can access the webcast through Bruker's investor relations website or via telephone. A replay will be available starting one hour after the call until June 4, 2022. Bruker continues to support scientific innovation and diagnostics in various research fields.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.20%
Tags
-
Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) has unveiled innovative technologies at the AACR Annual Meeting 2022, focusing on spatial multiomics and single-cell proteomics for cancer research. Key launches include the MALDI HiPLEX-IHC tissue imaging solution, which integrates protein mapping with small molecule imaging, and the CellScape™ platform for high-precision spatial proteomics. The timsTOF fleX platform can identify over 13,000 proteins, advancing the capabilities in cancer profiling. These advancements position Bruker to enhance cancer research methodologies significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
none
-
Rhea-AI Summary

Bruker Corporation (BRKR) has successfully acquired IonSense Inc., a leader in ambient DART ionization technology. This acquisition aims to enhance the development of DART ionization sources and expand applications in food analysis and forensics. IonSense will leverage Bruker's financial investments to accelerate their product development and reach a broader market. The DART technology uniquely analyzes solids, liquids, and gases without prior chromatography, offering faster sample identification. This merger positions Bruker to further tap into the $4B mass spectrometry marketplace.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
Rhea-AI Summary

Bruker Corporation (NASDAQ: BRKR) has announced the acquisition of Optimal Industrial Automation and Technologies, enhancing its role in pharmaceutical process analytical technology (PAT) and manufacturing automation. The acquisition is expected to complement Bruker's existing offerings in high-value NMR and mass spectrometry, positioning them as a key software provider for the biopharma sector. While financial specifics were not disclosed, Optimal's 2022 revenue is projected at $10 million, with anticipated positive impacts on Bruker's revenue and operating margins.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags

FAQ

What is the current stock price of Bruker (BRKR)?

Bruker (BRKR) last closed at $61.59.

What is the market cap of Bruker (BRKR)?

The market cap of Bruker (BRKR) is approximately $9.4B.